Presentation by Stephen O'Hara, Founder & CEO, OptiBiotix Health PLC

Next generation clinically proven probiotics for specific health conditions: cardiovascular health

Share this article:

A systematic and pharma-based approach to strain rationale, identification and selection

Lactobacillus plantarum LP-LDL is a probiotic identified using a systematic discovery process. Its efficacy in lowering cholesterol and systolic blood pressure has been demonstrated in three published human studies. The results of these studies will be presented. The use of pharmaceutical type discovery platforms to screen large numbers of probiotics for a mechanism of action and improvements in established clinical biomarkers for a health condition narrows the gap between supplements and pharmaceutical products.